Picture of BioMark Diagnostics logo

BUX — BioMark Diagnostics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-20.69%
3m-25.17%
6m-32.33%
1yr+10.24%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-34.38%
50d MA-17.92%
200d MA-16.63%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value78.3
Price to Tang. Book78.3
Price to Free Cashflown/a
Price to Sales1,608.16
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-118.48%
Return on Equity-149.87%
Operating Margin-6386.26%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202731st Mar 2028
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2027 / 2028

Blurred out image of BioMark Diagnostics EPS forecast chart

Profile Summary

BioMark Diagnostics Inc. is a developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The Company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. It is also engaged in developing accessible diagnostic solutions to address unmet medical needs in oncology. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a liquid biopsy metabolic panel assay, which is instrumental for early-stage diagnosis of lung cancer.

Directors

Last Annual
March 31st, 2026
Last Interim
June 30th, 2026
Incorporated
June 19th, 2014
Public Since
November 3rd, 2014
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
106,483,435

BUX Share Price Performance

Similar to BUX

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of BetterLife Pharma logo

BetterLife Pharma

ca flag iconCanadian Securities Exchange

Picture of Biomind Labs logo

Biomind Labs

ca flag iconCanadian Securities Exchange

Picture of Biovaxys Technology logo

Biovaxys Technology

ca flag iconCanadian Securities Exchange

FAQ